Advertisement

Topics

Latest "ConSynance Therapeutics, Inc." News Stories

09:41 EDT 19th September 2018 | BioPortfolio

Here are the most relevant search results for "ConSynance Therapeutics, Inc." found in our extensive news archives from over 250 global news sources.

More Information about ConSynance Therapeutics, Inc. on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about ConSynance Therapeutics, Inc. for you to read. Along with our medical data and news we also list ConSynance Therapeutics, Inc. Clinical Trials, which are updated daily. BioPortfolio also has a large database of ConSynance Therapeutics, Inc. Companies for you to search.

Showing "ConSynance Therapeutics" News Articles 1–25 of 7,800+

Wednesday 19th September 2018

Targeted Oncology™ Launches its Latest Virtual Tumor Board on Multiple Myeloma

Distinguished experts to provide in-depth insights on four patients with multiple myeloma Targeted Oncology™, a print and digital resource that offers content and expert opinions on standard and emerging treatments in the oncology field, will launch its third “Expert Perspective: Virtual Tumor Board” on Monday, September 24. Each Virtual Tumor Bo...


Maryland Tech Council Appoints Marty Rosendale Chief Executive Officer

The Maryland Tech Council (MTC), the state’s largest trade association supporting the technology and life sciences sectors, today announced the appointment of Marty Rosendale as Chief Executive Officer (CEO), effective immediately. “Marty is a long-time member of MTC and served as senior executive advisor of the Tech Council of Maryland...

Cerebrum Therapeutics Wins Biotech Startup Pitch Competition Co-Sponsored by Scientist.com and iPEPS-ICM

France-based company takes top honors in startup competition for early stage biotechs accelerating CNS disease research Scientist.com, the life science industry’s leading online marketplace for outsourced research, and the Brain and Spine Institute incubator, iPEPS-ICM, the first innovation accelerator dedicated to brain diseases in


Synedgen Appoints Kaveri Parker, Ph.D. as Chief Business Officer

Synedgen, a company leveraging its proprietary glycomics technology platform to develop glycopolymer-based therapeutics for infectious and inflammatory conditions, today announced the appointment of Kaveri Parker, Ph.D. as Chief Business Officer. In her role, she will lead the business development and commercialization of Synedgen’s inflammatory and ...

Secarna Pharmaceuticals successfully hosted Inaugural Industry Expert Meeting and Networking Event for the Oligonucleotide Therapeutics Society (OTS) in Munich

DGAP-News: Secarna Pharmaceuticals GmbH & Co. KG / Key word(s): Conference 19.09.2018 / 11:30 The issuer is solely responsible for the content of this announcement. Secarna Pharmaceuticals successfully hosted Inaugural Industry Expert Meeting and Networking Event for the Oligonucleotide Therapeutics Society (OTS) in Munich   Secarna provided a platform for discussion and informa...

Norgine buys rights to sell Shield’s iron deficiency therapy

Norgine has signed a deal with Shield Therapeutics allowing it to commercialise iron deficiency therapy Feraccru in Europe, Australia and New Zealand.

Zymeworks Names Anthony Polverino, Ph.D., Executive Vice President of Early Development and Chief Scientific Officer

Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced it has named Anthony (Tony) Polverino, Ph.D., Executive Vice President of Early Development and Chief Scientific Officer. In his new role, Dr. Polverino will be instrumental in setting and driving Zymeworks’ R&D strategy. He ...

Registrations are closing soon for next week's @CamNTF at Granta Park hosted by @AstraZeneca. Come to hear updates from Prof Slave Petrovski, Dr Dimitrios Vitsios and Dr Eleanor Wigmore on genomic approaches to therapeutics development. Register here:…

Registrations are closing soon for next week's @CamNTF at Granta Park hosted by @AstraZeneca. Come to hear updates from Prof Slave Petrovski, Dr Dimitrios Vitsios and Dr Eleanor Wigmore on genomic approaches to therapeutics development. Register here: …https://camntfseptember18event.eventbrite.co.uk 

Immunomic Therapeutics Senior Vice President of R&D to Participate in Bio+Tech Conference

Sr. VP of R&D will discuss lysosomal targeting technology as applied in cancer immunotherapy Tomorrow, Teri Heiland, Ph.D., Senior Vice President of Research and Development at Immunomic Therapeutics, Inc. will participate in the Cancer Immunotherapeutics panel at the Bio+Tech18 Conference in Baltimore, Maryland. Dr. Heiland and panelists from VLP ...

MiNA Therapeutics Announces Findings From MTL-CEBPA Clinical Trial in Patients with Advanced Liver Cancer at International Liver Cancer Association Conference

--Oral presentation by trial’s Chief Investigator describes complete tumour responses reported in patients off-study when subsequently administered standard of care-- --MiNA plans to amend current trial protocol to clinically evaluate MTL-CEBPA in combination with current standard of care for advanced liver cancer-- MiNA Therapeutics,...

DermTech Announces Enrollment Completion of Clinical Study to Assess DNA Damage and Reversal

DermTech, Inc., the global leader in non-invasive molecular dermatology, announced today it has completed enrollment in a clinical study to assess DNA damage induced by an excimer laser and evaluate the potential of topical agents T4 endonuclease and photolyase to reduce DNA damage induced as measured through gene expression analysis. The study is being co...

Abzena Announces a Research and Licence Agreement with Tmunity Therapeutics, a T Cell Engineering Company

Abzena, plc (AIM: ABZA, Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has signed an antibody humanisation agreement with Tmunity Therapeutics (Tmunity), a clinical stage T cell therapy company and a leader in the development of new Chimeric Antigen Receptor T...

UTILITY Receives Investigational New Drug Approval from US FDA

UTILITY therapeutics Ltd (“UTILITY” or “the Company”), a pharmaceutical company focused on developing and commercialising antibiotics in the US, today announces that the US Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) applications for mecillinam (injectable) and pivmecillinam (oral prodrug). This enables the Company ...

Tuesday 18th September 2018

Spectrum To Test Poziotinib's Potential As First Line Treatment Of Exon 20 Mutant NSCLC

Spectrum is expanding a clinical trial with its novel, oral pan-HER inhibitor poziotinib into the first-line treatment of NSCLC with...   

Executives On The Move: New CEOs Vaxil Bio and Akero Therapeutics, with Some Big Pharma Execs Joining Smaller Companies

This week’s appointments include a new chief business officer at Sutro Biopharma and a new chief medical officer at Crescendo...   

AIT Therapeutics Presented Nitric Oxide Data at the European Respiratory Society International Congress 2018

GARDEN CITY, N.Y. and REHOVOT, Israel, Sept. 19, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (OTCQB: AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced two poster presentations on inhaled NO ...

Spero Therapeutics to Present at the Cantor Global Healthcare Conference in October

CAMBRIDGE, Mass., Sept. 19, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant bacterial infections, announced today that Joel Sendek, Chief Financial Officer of Spero Therapeutics, will provide a corporate update at the 2018 Cantor...

Ovid Therapeutics to Present at Two Investor Healthcare Conferences in October 2018

NEW YORK, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the company will present at two upcoming investor conferences in October: Cantor Fitzgerald Global Healthcare ConferenceThe company will give a corporate presen...

Immunomic Therapeutics to Present at the 2018 China BioMed Innovation and Investment Conference

Presentation to Highlight UNITE technology application to oncology Today, Sia Anagnostou, Head, China Corporate Development of Immunomic Therapeutics, Inc. (ITI) and Senior Scientist Yan Su will present at the 2018 China BioMed Innovation and Investment Conference in Suzhou, China. ITI is pioneering the study of the LAMP-based nucleic acid immunotherapy ...

3-Year Clinical Outcomes and BPH Subgroup Analysis of Profound Medical’s Phase I Clinical Trial to be Included in Presentation at DGU 2018

TORONTO, Sept. 18, 2018 (GLOBE NEWSWIRE) — Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time Magnetic Resonance (“MR”) imaging combined with the safety and ablation … Continue reading → Cet article 3-Year Clinical Outcomes and BPH Subgroup Analysis o...

BioClin Therapeutics Announces New Leadership to Advance Late-Stage Bladder Cancer Development Program

BioClin Therapeutics, Inc., a privately-held clinical stage drug development company, today announced the appointment of Scott Myers as Chief Executive Officer, and Julie Eastland as Chief Financial Officer and Chief Business Officer. Mr. Myers will also continue in his role as company Chairman. “We are excited to announce the appointment of Sco...

Non Malignant pain Global Clinical Trials Review, H1, 2018 [Report Updated: 31032018] Prices from USD $2500

Non Malignant pain Global Clinical Trials Review, H1, 2018SummaryGlobalData's clinical trial report, Non Malignant pain Global Clinical Trials Review, H1, 2018" provides an overview of Non Malignant pain clinical trials scenario. This report provides top line data relating to the clinical trials on Non Malignant pain. Report includes an overview of trial numbers and their average enrollment in top...

NIH Funds Hingez Therapeutics to Develop New Cholesterol Pill

Hingez’s Approach May Lead to Better Solutions for Treating High-Cholesterol, Other Diseases WASHINGTON (PRWEB) September 18, 2018 In August, Hingez Therapeutics Inc. received a grant totaling more than 1.8 million from the National Institutes of Health (NIH) to develop oral drugs to treat high cholesterol, with the goal of reaching human trials within two to three years. “Hingez Therapeutic...

CRISPR Therapeutics and Viacyte launch diabetes partnership

NASH Race Heats up as Viking Therapeutics Announces Stellar Phase II Data http://dlvr.it/QkbTsZ pic.twitter.com/qOvFosyEmr

NASH Race Heats up as Viking Therapeutics Announces Stellar Phase II Data http://dlvr.it/QkbTsZ  pic.twitter.com/qOvFosyEmr


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks